Table 2.
Specific Patient Characteristics
| UPN | Sex | Diagnosis | Pre-HCT Status, BM Disease Burden | Plerixafor + NK Cells | Subsequent Cell Infusions | PB Chimeris m %Donor Day +30 | Acute GVHD | Chronic GVHD | Outcome | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Organs | Grade | Organs | Grade | ||||||||
| 1 | F | AML/MDS | CR1, 3% | N | DLI (7) | 100% | Alive, CR | ||||
| 2 | F | B-ALL | CR2, 1 × 10−5* | N | 100% | Skin | I | Relapse | |||
| 3 | F | B-ALL | CR2, 2% | N | 100% | Gut, skin | II | Skin | Mild | TRM | |
| 4 | M | B-ALL | Relapse 1, 8% | N | 100% | Gut, skin | IV | TRM | |||
| 5 | F | AML | Relapse 1, Hypocellular^ | Y | 99–100% | Skin | I | Relapse | |||
| 6 | F | AML | CR2, 2% | Y | 100% | GI, oral, MSK, skin, lung | Severe | Alive,CR | |||
| 7 | M | B-ALL | Relapse 2,72% | Y | Boost(1) | 100% | Liver | IV | Relapse | ||
| 8 | F | AML | Relapse 1,16% | Y | 99–100% | Liver | III | TRM | |||
| 9 | F | B-ALL | CR2,<0.01% | Y | DLI (3) Boost (2) | 100% | TRM | ||||
| 10 | F | B-ALL | CR2,<0.01% | Y | NE | TRM | |||||
| 11 | F | AML | Relapse 1,41% | Y | DLI (2) | 100% | Relapse | ||||
| 12 | M | AML | Relapse 1,57% | Y | DLI (3) Boost (1) | 9% | Refractory | ||||
| 13 | M | AML | Relapse 1,63% | Y | 90% | Skin | I | Refractory | |||
| 14 | F | AML | Relapse 1,76% | Y | 100% | Relapse | |||||
| 15 | M | AML | CR2, 1% | Y | 100% | Skin | I | Relapse | |||
| 16 | M | AML | Relapse 1,61% | Y | DLI (1) | NE | Refractory | ||||
| 17 | M | T-ALL | CR2,<0.01% | Y | DLI (2) | 100% | Relapse | ||||
| 18 | M | AML | Relapse 1,43% | Y | 100% | Relapse | |||||
| 19 | F | AML | Ref, PIF, 12% | Y | DLI (2) | 100% | Skin, gut | III | Relapse | ||
| 20 | M | JMML | Relapse 1,0%$ | Y | 100% | Gut, liver, skin | III | Oral, skin, eye | Moderate | Alive,CR | |
| 21 | F | B-ALL | CR3,<0.01% | Y | 100% | Gut, skin | II | Lung | Severe | Alive,CR | |
| 22 | F | AML | CR3,1 × 10−3* | N | 100% | Eye, skin, gut | Moderate | TRM | |||
UPN = unique participant number; HCT = hematopoietic cell transplant; PB = peripheral blood, unsorted; GVHD = graft-versus-host disease; BM = bone marrow; F = female; M = male; AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; ALL = acute lymphoid leukemia; JMML = juvenile myelomonocytic leukemia; CR = complete remission; Ref = refractory; PIF = partial induction failure; DLI = donor lymphocyte infusion; Y = yes; N = no; N/A = not available; boost = HPC product; NE = not evaluable; TRM = treatment-related mortality; MSK = musculoskeletal; mod = moderate
Detectable by PCR, negative by flow cytometry.
Leukemic blasts present
Left-shifted myeloid maturation, anemia, thrombocytopenia, and falling chimerism with no increased blasts